Kaspar RL - Search Results

1

Clinical and pathological features of pachyonychia congenita.

Leachman SA, Kaspar RL, Fleckman P, Florell SR, Smith FJ, McLean WH, Lunny DP, Milstone LM, van Steensel MA, Munro CS, O'Toole EA, Celebi JT, Kansky A, Lane EB. Leachman SA, et al. Among authors: kaspar rl. J Investig Dermatol Symp Proc. 2005 Oct;10(1):3-17. doi: 10.1111/j.1087-0024.2005.10202.x. J Investig Dermatol Symp Proc. 2005. PMID: 16250204 Free article. Review.

2

Syntheses of puromycin from adenosine and 7-deazapuromycin from tubercidin, and biological comparisons of the 7-aza/deaza pair.

Robins MJ, Miles RW, Samano MC, Kaspar RL. Robins MJ, et al. Among authors: kaspar rl. J Org Chem. 2001 Nov 30;66(24):8204-10. doi: 10.1021/jo010935d. J Org Chem. 2001. PMID: 11722226

3

Purification and physical analysis of Bacillus anthracis plasmids pXO1 and pXO2.

Kaspar RL, Robertson DL. Kaspar RL, et al. Biochem Biophys Res Commun. 1987 Dec 16;149(2):362-8. doi: 10.1016/0006-291x(87)90375-5. Biochem Biophys Res Commun. 1987. PMID: 3122734

4

Challenges in developing therapies for rare diseases including pachyonychia congenita.

Kaspar RL. Kaspar RL. J Investig Dermatol Symp Proc. 2005 Oct;10(1):62-6. doi: 10.1111/j.1087-0024.2005.10208.x. J Investig Dermatol Symp Proc. 2005. PMID: 16250210 Free article. Review.

5

SiRNA-mediated selective inhibition of mutant keratin mRNAs responsible for the skin disorder pachyonychia congenita.

Hickerson RP, Smith FJ, McLean WH, Landthaler M, Leube RE, Kaspar RL. Hickerson RP, et al. Among authors: kaspar rl. Ann N Y Acad Sci. 2006 Oct;1082:56-61. doi: 10.1196/annals.1348.059. Ann N Y Acad Sci. 2006. PMID: 17145926

6

Development of therapeutic siRNAs for pachyonychia congenita.

Smith FJ, Hickerson RP, Sayers JM, Reeves RE, Contag CH, Leake D, Kaspar RL, McLean WH. Smith FJ, et al. Among authors: kaspar rl. J Invest Dermatol. 2008 Jan;128(1):50-8. doi: 10.1038/sj.jid.5701040. Epub 2007 Aug 30. J Invest Dermatol. 2008. PMID: 17762855 Free article.

7

Single-nucleotide-specific siRNA targeting in a dominant-negative skin model.

Hickerson RP, Smith FJ, Reeves RE, Contag CH, Leake D, Leachman SA, Milstone LM, McLean WH, Kaspar RL. Hickerson RP, et al. Among authors: kaspar rl. J Invest Dermatol. 2008 Mar;128(3):594-605. doi: 10.1038/sj.jid.5701060. Epub 2007 Oct 11. J Invest Dermatol. 2008. PMID: 17914454 Free article.

8

Therapeutic siRNAs for dominant genetic skin disorders including pachyonychia congenita.

Leachman SA, Hickerson RP, Hull PR, Smith FJ, Milstone LM, Lane EB, Bale SJ, Roop DR, McLean WH, Kaspar RL. Leachman SA, et al. Among authors: kaspar rl. J Dermatol Sci. 2008 Sep;51(3):151-7. doi: 10.1016/j.jdermsci.2008.04.003. Epub 2008 May 20. J Dermatol Sci. 2008. PMID: 18495438 Free PMC article. Review.

9

Rapamycin selectively inhibits expression of an inducible keratin (K6a) in human keratinocytes and improves symptoms in pachyonychia congenita patients.

Hickerson RP, Leake D, Pho LN, Leachman SA, Kaspar RL. Hickerson RP, et al. Among authors: kaspar rl. J Dermatol Sci. 2009 Nov;56(2):82-8. doi: 10.1016/j.jdermsci.2009.07.008. Epub 2009 Aug 21. J Dermatol Sci. 2009. PMID: 19699613

10

Achieving successful delivery of nucleic acids to skin: 6th Annual Meeting of the International Pachyonychia Congenita Consortium.

Kaspar RL, McLean WH, Schwartz ME. Kaspar RL, et al. J Invest Dermatol. 2009 Sep;129(9):2085-7. doi: 10.1038/jid.2009.220. J Invest Dermatol. 2009. PMID: 19809420 Free article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

80 results

Search Page